| Document |
Document Title |
|
WO/2023/180575A1 |
The invention relates to solid dispersions for oral administration comprising a bradykinin B2 receptor antagonist having a chemical structure according to Formula (1), or a salt or solvate thereof, wherein R is deuterium or hydrogen: For...
|
|
WO/2023/183059A1 |
The present invention provides a method of treating pathological inflammation in a patient comprising: administering to the patient a multivalent structured polypeptide comprising at least one therapeutic peptide. The present invention a...
|
|
WO/2023/181755A1 |
Provided is: a highly-safe and low-cost expression regulator for a factor particularly involved in maturation, moisture retention, or barrier function of the skin; an expression enhancer for an antimicrobial peptide; an expression enhanc...
|
|
WO/2023/182468A1 |
The present disclosure provides a wound treatment composition and the like. N-(\{2-[4-(difluoromethoxy)-3-(propan-2-yloxy)phenyl]-1,3-ox
azol-4-yl\}methyl)-2-ethoxybenzamide or a salt thereof is useful as an active ingredient of the woun...
|
|
WO/2023/180214A1 |
The invention relates to compositions, particularly topical compositions comprising a urolithin, cosmetic compositions comprising a urolithin and cosmetic compositions comprising a urolithin and trehalose, compositions comprising urolith...
|
|
WO/2023/183901A1 |
Compounds, compositions thereof, and methods of using the same in dosing protocols for the inhibition of TYK2, and the treatment of inflammatory disorders including psoriasis and psoriatic arthritis are described.
|
|
WO/2023/114833A9 |
The instant disclosure provides selective Treg stimulator compositions, including RUR20kD-IL-2 and related compositions, and rezpegaldesleukin, and formulations and dosing regimens for methods of using these compositions, for example, fo...
|
|
WO/2023/174447A1 |
Disclosed are a mesenchymal stem cell wound repair dominant functional cluster (Hr-MSC), identification thereof, and an application. The mesenchymal stem cell wound repair dominant functional cluster has a biomarker combination comprisin...
|
|
WO/2023/178219A1 |
The present disclosure concerns use of activated or inactivated fibroblasts or fibroblast-derived materials, such as exosomes from fibroblasts, for wound care. The methods and compositions are useful for purpose of tissue differentiation...
|
|
WO/2023/174205A1 |
The present invention relates to a pharmaceutical formulation and use thereof, belonging to the field of pharmacy. The pharmaceutical formulation has significant effects in preventing and treating renal diseases, eye diseases, ulcerative...
|
|
WO/2023/178256A1 |
The present disclosure relates to methods for treating plexiform neurofibromas associated with neurofibromatosis type 1 (NF1-PN), comprising administering to a pediatric patient (e.g., 2 to 15 years of age) in need thereof mirdametinib o...
|
|
WO/2023/177207A1 |
The present invention relates to a scalp or hair care composition comprising a nano-carbon structure, and the nano-carbon structure of the present invention can retain moisture of the scalp or hair even in a small amount, and relieve inf...
|
|
WO/2023/178099A1 |
Described herein are NLRP3 modulators and methods of utilizing NLRP3 modulators in the treatment of diseases, disorders or conditions. Also described herein are pharmaceutical compositions containing such compounds.
|
|
WO/2023/176952A1 |
The purpose of the present invention is to provide a means for controlling the proliferation of a bacterium in the intestine. Provided is a composition for controlling the proliferation of any one bacterium selected from the group consis...
|
|
WO/2023/176951A1 |
Provided is a means for controlling proliferation of Collinsella bacteria in the intestines. The present invention addresses the problem of providing a novel material that is capable of controlling proliferation of Collinsella bacteria. ...
|
|
WO/2023/177625A1 |
Disclosed herein are shelf-stable formulations comprising benzoyl peroxide in a formulation effective to reduce or prevent degradation of the benzoyl peroxide to benzene. Further provided herein are methods of preventing or reducing degr...
|
|
WO/2023/178269A1 |
The present disclosure relates to methods for treating cutaneous neurofibromas (cNF) comprising administering to a patient in need thereof mirdametinib or a pharmaceutically acceptable salt thereof.
|
|
WO/2023/174981A1 |
The present invention relates to an aqueous extract obtained from a plant of the genus Aster for cosmetic or therapeutic applications, in particular in the prevention and/or treatment of acne.
|
|
WO/2023/174039A1 |
Disclosed herein are anti-MASP-2 antibodies and antigen-binding fragments, polynucleotides encoding the antibodies and antigen-binding fragments, and pharmaceutical compositions comprising the antibodies and antigen-binding fragments. Us...
|
|
WO/2023/176796A1 |
The problem to be solved by the present invention is to provide a novel scar formation inhibitor having, as an active ingredient, a compound that has not been conventionally known to have an effect for inhibiting scar formation. The pres...
|
|
WO/2023/178001A1 |
There are methods, dosage regimens, and compositions for treating hidradenitis suppurativa.
|
|
WO/2023/174265A1 |
Provided are a recombinant adeno-associated virus for treating inflammatory diseases, and a construction method therefor and the use thereof. The recombinant adeno-associated virus uses an adeno-associated virus as a vector, and comprise...
|
|
WO/2023/174314A1 |
Provided is the use of a compound of formula I, a pharmaceutically acceptable salt, a stereoisomer, a polymorph, a solvate, a metabolite or a prodrug thereof, or a composition thereof in the preparation of a drug for treating alopecia su...
|
|
WO/2023/174409A1 |
The present invention relates to a salt form and a crystal form of a Vanin enzyme inhibitor represented by formula I, a method for preparing same, and use thereof. The salt form is a salt formed by the compound represented by formula I w...
|
|
WO/2023/174463A1 |
The present invention provides a method of preparation of a biological therapeutic product based on perinatal tissue, characterized in that the method includes the steps of: a) cleaning of the starting perinatal tissue and optionally its...
|
|
WO/2023/176950A1 |
Provided is a means for controlling the proliferation of any one bacterium selected from the group consisting of a bacterium belonging to the genus Faecalibacterium, a bacterium belonging to the genus Akkermansia, a bacterium belonging t...
|
|
WO/2023/170109A1 |
The present invention relates to novel compositions and methods of treating clinical conditions arising from GNAQ and GNA11 somatic mutations including cancer, Sturge-Weber syndrome (SWS), Phakomatosis Pigmentovascularis (PPV), Extensive...
|
|
WO/2023/172215A1 |
The invention relates to a cosmetic product to be used in especially the treatment of wounds, burns and skin inflammation and for providing cleaning, tightening, moisturizing and regeneration of the skin, and to the use of this cosmetic ...
|
|
WO/2023/168948A1 |
Disclosed is the use of Pulsatilla chinensis saponin B4 in the preparation of a topical drug for treating psoriasis. The topical drug is prepared by using Pulsatilla chinensis saponin B4 as the active ingredient, and is convenient to use...
|
|
WO/2023/170597A1 |
There is described a topical composition for treating injuries or cutaneous inflammatory states or proctological pathologies, comprising butyric acid or a salt thereof at a fraction by weight between 1% and 50% and zinc oxide at a fracti...
|
|
WO/2023/169260A1 |
Provided are a ginseng composition having high utilization of ginsenoside, and a preparation method and an application of the composition. The composition is composed of ginseng powder of 250 meshes or more and β-cyclodextrine, and the ...
|
|
WO/2023/169594A1 |
Provided in the invention is an application of a blood-derived sample in the preparation of vesicles, and an application of a lysis solution in the preparation of vesicles. Also provided is the obtained vesicles, a composition containing...
|
|
WO/2023/168608A1 |
A pharmaceutical composition including a retinoic acid and a carbohydrate is provided. The pharmaceutical composition may further include a metal ion. Use of the pharmaceutical composition in the manufacture of a medicament for inhibitin...
|
|
WO/2023/166172A1 |
The present invention relates to a compound according to formula (I) and pharmaceutically acceptable salts, hydrates, or solvates thereof. The invention further relates to said compounds for use in therapy, to pharmaceutical compositions...
|
|
WO/2023/167537A1 |
The present invention relates to a pharmaceutical composition for preventing or treating skin diseases caused by radiation irradiation, comprising darapladib or a pharmaceutically acceptable salt thereof as an active ingredient. Daraplad...
|
|
WO/2023/168006A1 |
Compositions comprising exosomes, growth factors, and fragments of mesenchymal stem cells (MSCs), and their use for the cosmetic and/or therapeutic treatment of skin are provided. Methods for preparing the compositions are also provided.
|
|
WO/2023/165052A1 |
Provided is a directionally driven hemostatic microsphere with a puncture function, which comprises hollow pollen and a power system assembled on the surface of the hollow pollen, wherein the surface of the hemostatic microsphere is need...
|
|
WO/2023/167066A1 |
[Problem] To find a novel pharmaceutical or method for treating autoimmune diseases. [Solution] A combination of methotrexate and 5-ALAs.
|
|
WO/2023/167503A1 |
The present invention relates to a transdermal dosage form, for promoting local blood flow, of a dual-acting PDE5 inhibitor/organic nitrate ester, and, more specifically, to: use, for preventing or treating various symptoms or diseases i...
|
|
WO/2023/168418A1 |
The present invention relates to recombinant targeting peptides, compositions comprising said targeting peptides and methods of targeted delivery of therapeutics suitable for the control, improvement and/or treatment of acne. More partic...
|
|
WO/2023/167867A1 |
The present disclosure relates to the field of personal care and more particularly to a method for improving scalp condition and hair growth, which comprises applying to the scalp a composition comprising an active agent selected among s...
|
|
WO/2023/166274A1 |
The invention relates to pharmaceutical compositions comprising L-epinephrine or a pharmaceutically acceptable salt thereof; and a carrier vehicle comprising ethanol and water. The pharmaceutical composition has a molecular oxygen concen...
|
|
WO/2023/166268A1 |
The present invention relates to 5,6,5',6'-tetraphenyl-3,3'-(1,4-phenylene)-bis[1,2,4]triazin
e, or a composition comprising same, for the use thereof in strengthening the skin barrier and/or preventing and/or reducing damage to the barr...
|
|
WO/2023/167082A1 |
Provided are: a method for producing hair follicle mesenchymal cells of which the number is increased and the hair regeneration capability is restored; and a use of the hair follicle mesenchymal cells. The method for producing proliferat...
|
|
WO/2023/165493A1 |
Disclosed are a naphthyridine derivative and use thereof. The naphthyridine derivative can well inhibit ATR kinase activity and can be used in the preparation of an ATR kinase inhibitor, particularly in the preparation of a medicament ag...
|
|
WO/2023/167122A1 |
The present invention mainly addresses the problem of providing a novel method for rapidly inducing growth factor-producing cells from somatic cells, that is, a novel production method that allows rapid production of growth factor-produc...
|
|
WO/2023/097398A9 |
A composition is provided for treating and/or preventing inflammation in a subject comprising A-type proanthocyanidin (PAC-A) and zinc. The composition can include between 0.001 wt% and 10 wt% of PAC-A, and between 0.01 wt% and 25 wt% of...
|
|
WO/2023/168004A1 |
Topical compositions including β-alanine and a transient receptor potential cation channel subfamily M (melastatin) member 8 (TRPM8) agonist, such as menthol, are disclosed. Also disclosed are methods of decreasing skin inflammation or ...
|
|
WO/2023/166013A1 |
The present invention relates to a topical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof wherein R1 is C1-C3alkyl, preferably methyl or ethyl, further preferably ethyl; R2 is H, CHO or CH=...
|
|
WO/2023/166348A1 |
Described herein are uses of crystalline forms of 2-(4-methoxy-3 -(3- methylphenethoxy)benzamido)-2,3-dihydro-1H-indene-2-carboxyl
ic acid in the treatment of diseases or conditions that would benefit by administration with an LPA1 recep...
|
